Remifentanil Protects against Lipopolysaccharide-Induced Inflammation through PARP-1/NF-κB Signaling Pathway

Sepsis is a leading cause of death in patients with severe infection worldwide. Remifentanil is an ultra-short-acting, potent opioid analgesic. In the study, we aimed to investigate the role and underlying mechanism of remifentanil in lipopolysaccharide- (LPS-) induced inflammation in human aortic e...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mediators Inflamm
Hlavní autoři: Zhang, Jian-ning, Ma, Yang, Wei, Xi-yan, Liu, Ke-yin, Wang, Hao, Han, Hui, Cui, Yi, Zhang, Ming-xiang, Qin, Wei-dong
Médium: Artigo
Jazyk:Inglês
Vydáno: Hindawi 2019
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7012251/
https://ncbi.nlm.nih.gov/pubmed/32082073
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/3013716
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky